InsidersTradesSigma
Track the Alkermes plc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Alkermes plc. has recorded 313 reports. Market capitalisation: €8.4bn. The latest transaction was reported on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Hopkinson Craig C.. The full history is free.
313
Insider Decl.
n/a
Thresholds
€1m
4 ops.
Buy Volume
€9m
36 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Alkermes plc. Buy (bullish), based on 17 analysts. Average price target: US$56.00.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,060 of 29,016 companies
60.9
score / 100
Value46
Quality75
FCF yld6.0%
Earn yld3.0%
EV/EBITDA24.2x
ROE3.9%
Gross mgn87%
Net mgn16%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 August 2026
Declarations313 total
7,576 shares@ US$49.2261Common StockSEC144:0001964306-26-000396
6,912 shares@ US$49.18510.0041% mcap11.1% of flowOrdinary SharesSEC:0001520262-26-000116:0
664 shares@ US$49.65260.0004% mcap1.1% of flowOrdinary SharesSEC:0001520262-26-000116:1
9,000 shares@ US$48.580.0053% mcap3.9% of flowOrdinary sharesSEC144:0001964306-26-000350
2,034 shares@ US$48.580.0012% mcap7.6% of flowCommon StockSEC144:0001964306-26-000351
44,472 shares@ US$50.3480.027% mcap33.8% of flowCommon StockSEC144:0001964306-26-000352
2,034 shares@ US$48.580.0012% mcap8.2% of flowOrdinary SharesSEC:0001520262-26-000109:0
16,524 shares@ US$46.720.0094% mcap17.6% of flowOrdinary SharesSEC:0001520262-26-000111:1
44,472 shares@ US$50.3480.027% mcap51.1% of flowOrdinary SharesSEC:0001520262-26-000111:2
104 shares@ US$19.340.0000% mcap0.0% of flowOrdinary SharesSEC:0001520262-26-000110:0
4,896 shares@ US$24.590.0015% mcap1.1% of flowOrdinary SharesSEC:0001520262-26-000110:1
9,000 shares@ US$48.580.0053% mcap4.1% of flowOrdinary SharesSEC:0001520262-26-000110:2
27,948 shares@ US$46.720.016% mcap29.8% of flowOrdinary SharesSEC:0001520262-26-000111:0
2,034 shares@ US$54.030.0013% mcap9.2% of flowCommon StockSEC144:0001964306-26-000311
2,034 shares@ US$54.030.0012% mcap7.1% of flowOrdinary SharesSEC:0001520262-26-000105:0
9,000 shares@ US$51.51340.0052% mcap4.7% of flowOrdinary sharesSEC144:0001964306-26-000304
5,000 sharesOrdinary SharesSEC:0001520262-26-000103:0
8,300 sharesOrdinary SharesSEC:0001520262-26-000103:1
700 sharesOrdinary SharesSEC:0001520262-26-000103:2
2,000 shares@ US$45.100.0010% mcap53.1% of flowCommon StockSEC144:0001964306-26-000282
2,000 sharesOrdinary SharesSEC:0001520262-26-000101:0
2,034 shares@ US$43.050.0010% mcap7.2% of flowCommon StockSEC144:0001964306-26-000268
2,034 shares@ US$43.050.0008% mcap6.0% of flowOrdinary SharesSEC:0001520262-26-000099:0
5,000 shares@ US$19.340.0018% mcap1.2% of flowOrdinary SharesSEC:0001520262-26-000097:0
9,000 shares@ US$41.67150.0070% mcap4.6% of flowOrdinary SharesSEC:0001520262-26-000097:1
25 of 313 declarations
About Alkermes plc.
Alkermes plc. (ticker: ALKS) is a biopharmaceutical company listed on the Nasdaq Global Select Market in the United States, with a strategic focus on neuroscience. Its global headquarters is in Dublin, Ireland, while the company maintains a significant operational and commercial footprint in the United States, where most of its marketing and execution capabilities are concentrated. Founded in 1987, Alkermes evolved from a specialty drug-delivery and formulation technology business into an integrated biopharma company combining development, manufacturing, and commercialization. For investors, it is best understood as a mid-cap specialty pharma name with a commercial base and a meaningful pipeline, exposed to psychiatric, addiction, and neurological disorders. ([alkermes.com](https://www.alkermes.com/about-us?utm_source=openai)) The commercial portfolio is centered on VIVITROL, ARISTADA/ARISTADA INITIO, and LYBALVI, which target long-standing unmet needs in alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Alkermes also highlights its manufacturing capabilities and royalty/manufacturing revenues, giving the group a hybrid profile that combines branded pharmaceuticals with product development and platform expertise. In recent company disclosures, Alkermes has emphasized that its portfolio and pipeline are focused on central nervous system disorders, with a strategy built around expanding existing brands and advancing new clinical assets. ([investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-third-quarter-2025-financial-results/?utm_source=openai)) From a competitive standpoint, Alkermes is a focused specialist rather than a broadly diversified large-cap pharma company. Its edge comes from a combination of established brands, medication-delivery know-how, and a commercial infrastructure geared toward therapeutic areas where adherence is often a major challenge. In antipsychotics and addiction medicine, the company competes in crowded markets, but its differentiated formulations and established market presence support a distinct positioning. The company also operates internationally, with activities in the United States, Ireland, and other regions, although its revenue base remains heavily tied to the U.S. market. ([stockanalysis.com](https://stockanalysis.com/stocks/alks/company/?utm_source=openai)) Recent developments are noteworthy. In 2026, Alkermes reported first-quarter results and said it expects to initiate a Phase 3 program for alixorexton in narcolepsy. That matters strategically because it shows the company is trying to broaden its pipeline beyond marketed products and pursue a new opportunity in sleep and neurology. The company continues to report quarterly performance updates and market disclosures that point to ongoing activity across its core franchises. In short, ALKS is a neuroscience-focused health care name listed on Nasdaq in the United States, with upside tied to both commercial execution and future clinical readouts. ([investor.alkermes.com](https://investor.alkermes.com/static-files/fff86401-d90f-4ef5-97ff-16775edb0cbe?utm_source=openai))
